C9 and amyotrophic lateral sclerosis: A limitation of this approach is that we cannot distinguish cell-type-specific alterations that represent direct effects of C9 mutation from end-of-life consequences of neurodegeneration and the resulting disease which are present in the C9-ALS or C9-FTD cases.